Prurigo nodularis (PN) is a chronic skin condition that produces intensely itchy, hard bumps on the body. These nodules form as a result of repeated scratching, but the itch that drives the scratching comes from deep dysfunction in the immune system and nerve signaling in the skin. It affects roughly 37 to 44 out of every 100,000 people in the United States, with nearly half of diagnosed patients being over age 65.
What the Nodules Look and Feel Like
The bumps of prurigo nodularis are firm, dome-shaped, and range from a few millimeters to a few centimeters across. They’re typically flesh-colored to pink, though on darker skin tones they can appear brown or hyperpigmented. They show up symmetrically on both sides of the body, most often on the outer surfaces of the arms and legs. The upper back, abdomen, and lower back can also be involved.
One distinctive clue is called the “butterfly sign.” Because patients can’t easily reach the center of their upper back, that area stays clear while the surrounding skin develops nodules, leaving a butterfly-shaped patch of unaffected skin. The palms, soles, face, and skin creases are also typically spared. The itch can be relentless, often described as the most distressing feature of the condition, far more than the appearance of the bumps themselves.
The Itch-Scratch Cycle
Prurigo nodularis is driven by a self-reinforcing loop between itch and scratching. The process starts with immune cells in the skin releasing signaling molecules that trigger intense itching. One key player is a molecule called IL-31, which is found at levels up to 50 times higher in PN skin compared to healthy skin. IL-31 directly activates itch-sensing nerve fibers and also stimulates those nerves to branch and sprout, expanding the network of fibers that can detect itch. The result is skin that becomes progressively more sensitive over time.
When you scratch in response to the itch, the mechanical damage thickens the skin and triggers more inflammation, which releases more itch signals. IL-31 also weakens the skin’s protective barrier by interfering with the genes that maintain it, and it activates cells called fibroblasts that deposit collagen, literally remodeling the tissue into the firm nodules characteristic of the disease. This means the nodules aren’t just a surface problem. They represent structural changes in the skin driven by ongoing immune and nerve activity.
The central nervous system is involved too. Itch receptors on nerves that run from the skin to the spinal cord transmit signals to the brain, and over time these pathways can become sensitized, so even mild stimuli produce intense itching. This central sensitization helps explain why the itch can feel so disproportionate and so difficult to ignore.
Who Gets Prurigo Nodularis
PN can occur at any age but is heavily weighted toward older adults. In U.S. data, roughly 47% of patients are over 65, and another 18 to 25% fall between ages 45 and 64. It can also appear in younger adults, with about 20 to 23% of cases occurring between ages 25 and 44. It’s relatively uncommon in children and teenagers.
Several underlying conditions are associated with PN. People with eczema (atopic dermatitis), kidney disease, liver disease, HIV, and other conditions that cause chronic itching are at higher risk. In many cases, PN develops on top of an existing itch condition that has gone on long enough for the scratch cycle to establish itself. Sometimes, however, no clear underlying cause is found.
How It Affects Daily Life
The toll of prurigo nodularis extends well beyond the skin. The constant itch disrupts sleep significantly. In a study comparing over 4,000 PN patients to matched controls, people with PN were 77% more likely to develop insomnia and 72% more likely to develop a sleep disorder overall. About 7.4% of PN patients were diagnosed with insomnia during follow-up, compared to 4.7% of people without the condition.
Mental health takes a hit as well. In the same study, major depression was more than twice as common among PN patients (3.2%) compared to controls (1.4%), and anxiety disorders affected about 7.9% of the PN group versus 5.4% of controls. Depression and anxiety aren’t just consequences of poor sleep; the chronic, unrelenting nature of the itch itself contributes directly. Many patients describe feeling trapped in a cycle they can’t escape, and the visible nodules can cause self-consciousness and social withdrawal.
How It’s Diagnosed
Prurigo nodularis is a clinical diagnosis, meaning a dermatologist identifies it based on the appearance and distribution of the nodules along with your history of chronic itching. There is no single lab test that confirms it. The characteristic dome-shaped, excoriated (scratched-open) nodules on the outer arms and legs, combined with sparing of hard-to-reach areas, create a recognizable pattern.
A skin biopsy is sometimes performed, particularly when bumps don’t respond to initial treatment or develop complications like bleeding or ulceration. Under the microscope, PN shows thickened skin layers, increased fibroblasts, and more blood vessels in the upper skin. However, these features overlap with other scratch-related conditions like lichen simplex chronicus, so the biopsy results always need to be interpreted alongside the clinical picture. Special testing called direct immunofluorescence can help rule out autoimmune blistering diseases that occasionally mimic PN.
Part of the diagnostic workup also involves looking for an underlying cause of the itch, which may include blood tests for kidney function, liver function, thyroid problems, or blood cell abnormalities.
Treatment Options
Treatment for PN has historically been difficult, but the landscape has changed substantially with newer therapies. The approach generally starts with topical treatments and escalates based on severity.
Topical and Localized Treatments
High-potency steroid creams applied directly to nodules are a common starting point. For stubborn, isolated nodules, a dermatologist may inject a steroid directly into the bump. This is typically done every three to four weeks. These injections work best when you have a limited number of nodules rather than widespread disease. Keeping the skin well moisturized and using anti-itch creams can help reduce the urge to scratch between treatments, which is essential for breaking the cycle.
Injectable Biologic Therapies
For moderate to severe PN, two biologic medications are now FDA-approved. Dupilumab (Dupixent) was the first, approved specifically for adults with PN. It works by blocking immune signals that drive both itch and inflammation. The treatment involves an initial loading dose followed by an injection every two weeks that patients give themselves at home.
Nemolizumab (Nemluvio) was approved based on two large clinical trials involving 560 patients. It targets the receptor for IL-31, the key itch-driving molecule in PN. In these trials, 56% of patients on nemolizumab in one study and 49% in the other achieved a clinically meaningful reduction in itch at 16 weeks, compared to just 16% on placebo. About 26 to 38% of treated patients achieved clear or nearly clear skin. The most common side effects were headache (6%), flare-ups of eczema, and a type of coin-shaped rash. Allergic reactions including facial swelling occurred in some patients.
These biologics represent a significant shift for people with PN. Before their approval, many patients cycled through treatments with limited relief. While neither medication works for everyone, the trial data shows that a substantial proportion of patients experience major improvements in both itch and nodule burden within a few months.
Breaking the Itch-Scratch Cycle at Home
Regardless of which medical treatment you use, disrupting the scratch habit matters. Keeping nails short reduces skin damage from unconscious scratching, especially during sleep. Wearing lightweight, breathable clothing over affected areas can provide a physical barrier. Cooling the skin with cold compresses or menthol-containing lotions can temporarily dampen itch signals. Some people find that covering nodules with bandages at night prevents scratching during sleep, which is when much of the damage occurs.
Stress is a well-recognized itch amplifier, and given the high rates of anxiety and depression in PN, addressing mental health is not a secondary concern. Cognitive behavioral therapy has been studied for chronic itch conditions and may help some patients develop strategies to manage the urge to scratch. The goal across all these measures is the same: reduce the mechanical trauma to the skin so that the immune and nerve changes driving the nodules have a chance to calm down.